Bispecific Anti-PSMA x Anti-CD3 Therapy for mCRPC Tumor Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for metastatic castration-resistant prostate cancer (mCRPC) are limited and ineffective, with a high unmet need for improved therapies that can inhibit tumor growth and prolong survival.

Innovation Solution

Administering a bispecific antibody that binds to prostate-specific membrane antigen (PSMA) and CD3, optionally combined with an anti-PD-1 antibody, to activate T cells and enhance immune response against PSMA-expressing tumors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If radiotherapeutics targeting PSMA (Yttrium-90 capromab, Lutetium-177 J591, MLN2704) are administered, then tumor growth is inhibited, but toxicity increases

Engineering Contradiction:

Improvetumor growth inhibitionVSAvoidtoxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an immune system intermediary mechanism where anti-CD3 antibodies and bispecific antibodies act as mediators to redirect T cells to PSMA-expressing tumors. This immune-mediated approach replaces direct radiotherapeutic killing, achieving tumor inhibition through biological immunity rather than physical radiation, thereby reducing direct tissue toxicity while maintaining anti-tumor efficacy

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/physical radiotherapeutic system (radiation delivery) with a biological immune system approach. Instead of using radioactive isotopes to physically destroy tumor cells, the invention employs antibody-mediated T cell activation to biologically eliminate tumors, substituting a mechanical energy-based system with a biological recognition and destruction system that offers reduced toxicity

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Ease of operation

If conventional therapies for metastatic castration-resistant prostate cancer are administered, then treatment is provided, but treatment effectiveness is limited and survival is not improved

Engineering Contradiction:

Improvetreatment availabilityVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent fundamentally changes the therapeutic parameter from androgen pathway inhibition (conventional therapy) to immune system activation (novel therapy). By shifting from blocking hormonal signals to engaging T cell-mediated immunity through anti-CD3 and bispecific antibodies, the treatment achieves superior effectiveness in metastatic castration-resistant prostate cancer where conventional therapies have failed

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite therapeutic approach combining multiple antibody types (anti-CD3 antibodies, bispecific anti-PSMA x anti-CD3 antibodies) and can be further combined with anti-PD-1 antibodies. This multi-component antibody composite strategy creates synergistic immune activation, overcoming the limitations of single-agent conventional therapies

Inventive Principle:

Principle #40Composite materials

3Reliability

If PD-1 signaling pathway is blocked, then immune surveillance is enhanced, but tumor escape mechanisms may develop

Engineering Contradiction:

Improveimmune surveillanceVSAvoidtumor escape capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by first activating T cells through anti-CD3 or bispecific antibody engagement before tumors can develop resistance mechanisms. This pre-emptive T cell activation occurs upstream in the immune response pathway, preventing tumor cells from adapting to PD-1 blockade alone and reducing the likelihood of escape mechanism development

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The bispecific antibody therapy effectively inhibits tumor growth, delays recurrence, and increases survival in patients with mCRPC, demonstrating synergistic anti-tumor effects when combined with anti-PD-1 antibodies.

Implementation Method 1

a bispecific antibody that specifically binds to prostate specific membrane antigen (PSMA) and CD3

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

Blockade of the PD-1 signaling pathway has demonstrated clinical activity in patients with multiple tumor types

Methodology Applied

Scientific EffectReceptor signaling blockade:

Data Source

PatentUS20250304714A1Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies

Publication Date: 2025.10.02 REGENERON PHARMACEUTICALS INC

AI summary

The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody or antigen-binding fragment thereof that specifically binds prostate-specific membrane antigen (PSMA) and CD3 alone or in combination with an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor.